Published in
Elsevier, The Lancet, 10094(390), p. 555-566
DOI: 10.1016/s0140-6736(17)31266-7
Links
Tools
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
Journal article published in 2017 by
H. Miles Prince,
Youn H. Kim,
Steven M. Horwitz,
Reinhard Dummer,
Julia Scarisbrick,
Pietro Quaglino,
Pier Luigi Zinzani,
Pascal Wolter,
Jose A. Sanches 
,
Pablo L. Ortiz-Romero,
Oleg E. Akilov,
Larisa Geskin,
Judith Trotman,
Kerry Taylor,
Stephane Dalle
and other authors.
,
Pablo L. Ortiz-Romero,
Oleg E. Akilov,
Larisa Geskin,
Judith Trotman,
Kerry Taylor,
Stephane Dalle
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 